Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
Since July 30, 2021, more than a million fully vaccinated Israeli residents who were 60 years of age or older have received a third dose of the BNT162b2 mRNA vaccine. As of August 31, the rate of confirmed Covid-19 infection was lower in the booster group than in the nonbooster group by a factor of...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2021-10, Vol.385 (15), p.1393-1400 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1400 |
|---|---|
| container_issue | 15 |
| container_start_page | 1393 |
| container_title | The New England journal of medicine |
| container_volume | 385 |
| creator | Bar-On, Yinon M Goldberg, Yair Mandel, Micha Bodenheimer, Omri Freedman, Laurence Kalkstein, Nir Mizrahi, Barak Alroy-Preis, Sharon Ash, Nachman Milo, Ron Huppert, Amit |
| description | Since July 30, 2021, more than a million fully vaccinated Israeli residents who were 60 years of age or older have received a third dose of the BNT162b2 mRNA vaccine. As of August 31, the rate of confirmed Covid-19 infection was lower in the booster group than in the nonbooster group by a factor of 11.3, and the rate of severe illness was lower by a factor of 19.5. |
| doi_str_mv | 10.1056/NEJMoa2114255 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_mms_n</sourceid><recordid>TN_cdi_proquest_journals_2579720119</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2579720119</sourcerecordid><originalsourceid>FETCH-LOGICAL-c560t-35224e6e067ab9a3eecca2ddace3c58969f38609956fb00074a507e1209ae23a3</originalsourceid><addsrcrecordid>eNqNkM1PFTEUxRuDkSe4dD-JYUVG-z3TDQlMUDEILtBtc6fvDvblTQttH4b_3uIjJCxI7OYu-jvnnnsIec_oR0aV_nRx-u17BM6Y5Eq9IgumhGilpHqHLCjlfSs7I3bJ25xXtD4mzRuyK6TiindqQY5_pFjQFR9DE6fm5OKKaT7y5hc45wM2JzHmgqmBa_Ahl2aId37ZMtP40JzlBLjeJ68nWGd89zj3yM_Pp1fD1_b88svZcHzeOqVpaYXiXKJGqjsYDQhE54Avl-BQONUbbSbRa2qM0tNYg3YSFO2QcWoAuQCxR462vjebccalw1ASrO1N8jOkexvB2-c_wf-21_HO9lIzpftq8OHRIMXbDeZiV3GTQs1suepMxyljplLtlnIp5pxwetrAqH1o3D5rvPL9lv-DY5yy8xgcPmnqIdpoKrT-V_7gCzxUPcRNKFV6-P_SSh9s6XnONuBqfiHQX_YYnGg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2579720119</pqid></control><display><type>article</type><title>Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel</title><source>Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>EZB-FREE-00999 freely available EZB journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Bar-On, Yinon M ; Goldberg, Yair ; Mandel, Micha ; Bodenheimer, Omri ; Freedman, Laurence ; Kalkstein, Nir ; Mizrahi, Barak ; Alroy-Preis, Sharon ; Ash, Nachman ; Milo, Ron ; Huppert, Amit</creator><creatorcontrib>Bar-On, Yinon M ; Goldberg, Yair ; Mandel, Micha ; Bodenheimer, Omri ; Freedman, Laurence ; Kalkstein, Nir ; Mizrahi, Barak ; Alroy-Preis, Sharon ; Ash, Nachman ; Milo, Ron ; Huppert, Amit</creatorcontrib><description>Since July 30, 2021, more than a million fully vaccinated Israeli residents who were 60 years of age or older have received a third dose of the BNT162b2 mRNA vaccine. As of August 31, the rate of confirmed Covid-19 infection was lower in the booster group than in the nonbooster group by a factor of 11.3, and the rate of severe illness was lower by a factor of 19.5.</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa2114255</identifier><identifier>PMID: 34525275</identifier><language>eng</language><publisher>WALTHAM: Massachusetts Medical Society</publisher><subject>Age ; Coronavirus ; Coronaviruses ; COVID-19 ; COVID-19 vaccines ; Disease transmission ; General & Internal Medicine ; Generalized linear models ; Illnesses ; Infections ; Infectious Disease ; Injection ; Life Sciences & Biomedicine ; Medicine, General & Internal ; mRNA ; Original ; Population ; Science & Technology ; Severe acute respiratory syndrome coronavirus 2 ; Vaccination ; Vaccines</subject><ispartof>The New England journal of medicine, 2021-10, Vol.385 (15), p.1393-1400</ispartof><rights>Copyright © 2021 Massachusetts Medical Society. All rights reserved.</rights><rights>Copyright © 2021 Massachusetts Medical Society. All rights reserved. 2021 Massachusetts Medical Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>832</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000696036600001</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c560t-35224e6e067ab9a3eecca2ddace3c58969f38609956fb00074a507e1209ae23a3</citedby><cites>FETCH-LOGICAL-c560t-35224e6e067ab9a3eecca2ddace3c58969f38609956fb00074a507e1209ae23a3</cites><orcidid>0000-0002-1053-4773</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa2114255$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2579720119?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,315,781,785,886,2760,2761,26108,27929,27930,39263,52387,54069,64390,64394,72474</link.rule.ids></links><search><creatorcontrib>Bar-On, Yinon M</creatorcontrib><creatorcontrib>Goldberg, Yair</creatorcontrib><creatorcontrib>Mandel, Micha</creatorcontrib><creatorcontrib>Bodenheimer, Omri</creatorcontrib><creatorcontrib>Freedman, Laurence</creatorcontrib><creatorcontrib>Kalkstein, Nir</creatorcontrib><creatorcontrib>Mizrahi, Barak</creatorcontrib><creatorcontrib>Alroy-Preis, Sharon</creatorcontrib><creatorcontrib>Ash, Nachman</creatorcontrib><creatorcontrib>Milo, Ron</creatorcontrib><creatorcontrib>Huppert, Amit</creatorcontrib><title>Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel</title><title>The New England journal of medicine</title><addtitle>NEW ENGL J MED</addtitle><description>Since July 30, 2021, more than a million fully vaccinated Israeli residents who were 60 years of age or older have received a third dose of the BNT162b2 mRNA vaccine. As of August 31, the rate of confirmed Covid-19 infection was lower in the booster group than in the nonbooster group by a factor of 11.3, and the rate of severe illness was lower by a factor of 19.5.</description><subject>Age</subject><subject>Coronavirus</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 vaccines</subject><subject>Disease transmission</subject><subject>General & Internal Medicine</subject><subject>Generalized linear models</subject><subject>Illnesses</subject><subject>Infections</subject><subject>Infectious Disease</subject><subject>Injection</subject><subject>Life Sciences & Biomedicine</subject><subject>Medicine, General & Internal</subject><subject>mRNA</subject><subject>Original</subject><subject>Population</subject><subject>Science & Technology</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Vaccination</subject><subject>Vaccines</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>HGBXW</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNkM1PFTEUxRuDkSe4dD-JYUVG-z3TDQlMUDEILtBtc6fvDvblTQttH4b_3uIjJCxI7OYu-jvnnnsIec_oR0aV_nRx-u17BM6Y5Eq9IgumhGilpHqHLCjlfSs7I3bJ25xXtD4mzRuyK6TiindqQY5_pFjQFR9DE6fm5OKKaT7y5hc45wM2JzHmgqmBa_Ahl2aId37ZMtP40JzlBLjeJ68nWGd89zj3yM_Pp1fD1_b88svZcHzeOqVpaYXiXKJGqjsYDQhE54Avl-BQONUbbSbRa2qM0tNYg3YSFO2QcWoAuQCxR462vjebccalw1ASrO1N8jOkexvB2-c_wf-21_HO9lIzpftq8OHRIMXbDeZiV3GTQs1suepMxyljplLtlnIp5pxwetrAqH1o3D5rvPL9lv-DY5yy8xgcPmnqIdpoKrT-V_7gCzxUPcRNKFV6-P_SSh9s6XnONuBqfiHQX_YYnGg</recordid><startdate>20211007</startdate><enddate>20211007</enddate><creator>Bar-On, Yinon M</creator><creator>Goldberg, Yair</creator><creator>Mandel, Micha</creator><creator>Bodenheimer, Omri</creator><creator>Freedman, Laurence</creator><creator>Kalkstein, Nir</creator><creator>Mizrahi, Barak</creator><creator>Alroy-Preis, Sharon</creator><creator>Ash, Nachman</creator><creator>Milo, Ron</creator><creator>Huppert, Amit</creator><general>Massachusetts Medical Society</general><general>Massachusetts Medical Soc</general><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1053-4773</orcidid></search><sort><creationdate>20211007</creationdate><title>Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel</title><author>Bar-On, Yinon M ; Goldberg, Yair ; Mandel, Micha ; Bodenheimer, Omri ; Freedman, Laurence ; Kalkstein, Nir ; Mizrahi, Barak ; Alroy-Preis, Sharon ; Ash, Nachman ; Milo, Ron ; Huppert, Amit</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c560t-35224e6e067ab9a3eecca2ddace3c58969f38609956fb00074a507e1209ae23a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Age</topic><topic>Coronavirus</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 vaccines</topic><topic>Disease transmission</topic><topic>General & Internal Medicine</topic><topic>Generalized linear models</topic><topic>Illnesses</topic><topic>Infections</topic><topic>Infectious Disease</topic><topic>Injection</topic><topic>Life Sciences & Biomedicine</topic><topic>Medicine, General & Internal</topic><topic>mRNA</topic><topic>Original</topic><topic>Population</topic><topic>Science & Technology</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Vaccination</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bar-On, Yinon M</creatorcontrib><creatorcontrib>Goldberg, Yair</creatorcontrib><creatorcontrib>Mandel, Micha</creatorcontrib><creatorcontrib>Bodenheimer, Omri</creatorcontrib><creatorcontrib>Freedman, Laurence</creatorcontrib><creatorcontrib>Kalkstein, Nir</creatorcontrib><creatorcontrib>Mizrahi, Barak</creatorcontrib><creatorcontrib>Alroy-Preis, Sharon</creatorcontrib><creatorcontrib>Ash, Nachman</creatorcontrib><creatorcontrib>Milo, Ron</creatorcontrib><creatorcontrib>Huppert, Amit</creatorcontrib><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bar-On, Yinon M</au><au>Goldberg, Yair</au><au>Mandel, Micha</au><au>Bodenheimer, Omri</au><au>Freedman, Laurence</au><au>Kalkstein, Nir</au><au>Mizrahi, Barak</au><au>Alroy-Preis, Sharon</au><au>Ash, Nachman</au><au>Milo, Ron</au><au>Huppert, Amit</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel</atitle><jtitle>The New England journal of medicine</jtitle><stitle>NEW ENGL J MED</stitle><date>2021-10-07</date><risdate>2021</risdate><volume>385</volume><issue>15</issue><spage>1393</spage><epage>1400</epage><pages>1393-1400</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>Since July 30, 2021, more than a million fully vaccinated Israeli residents who were 60 years of age or older have received a third dose of the BNT162b2 mRNA vaccine. As of August 31, the rate of confirmed Covid-19 infection was lower in the booster group than in the nonbooster group by a factor of 11.3, and the rate of severe illness was lower by a factor of 19.5.</abstract><cop>WALTHAM</cop><pub>Massachusetts Medical Society</pub><pmid>34525275</pmid><doi>10.1056/NEJMoa2114255</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-1053-4773</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2021-10, Vol.385 (15), p.1393-1400 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_journals_2579720119 |
| source | Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; EZB-FREE-00999 freely available EZB journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | Age Coronavirus Coronaviruses COVID-19 COVID-19 vaccines Disease transmission General & Internal Medicine Generalized linear models Illnesses Infections Infectious Disease Injection Life Sciences & Biomedicine Medicine, General & Internal mRNA Original Population Science & Technology Severe acute respiratory syndrome coronavirus 2 Vaccination Vaccines |
| title | Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T04%3A26%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_mms_n&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Protection%20of%20BNT162b2%20Vaccine%20Booster%20against%20Covid-19%20in%20Israel&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Bar-On,%20Yinon%20M&rft.date=2021-10-07&rft.volume=385&rft.issue=15&rft.spage=1393&rft.epage=1400&rft.pages=1393-1400&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMoa2114255&rft_dat=%3Cproquest_mms_n%3E2579720119%3C/proquest_mms_n%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2579720119&rft_id=info:pmid/34525275&rfr_iscdi=true |